About This Comparison
Our Editorial Standards
This hims vs medvi provider comparison is independently researched by our editorial team. We compare telehealth services based on publicly available information including pricing, available treatments, service areas, and verified customer reviews.
Not Medical Advice: This comparison is for informational purposes only. We are not healthcare providers. Always consult with a licensed physician before starting any treatment. Read our full medical disclaimer and editorial policy.
hims vs Medvi 2026: Multi-Category Men's Health Consolidation vs Medication-Only Budget Platform
hims and Medvi serve dramatically different healthcare needs: hims operates as complete men's health platform ($49-139/month consultations plus medication costs) with 7+ years operational history serving millions providing weight management integrated with erectile dysfunction, hair loss, mental health, skincare, and primary care through men's health specialized medical team, while Medvi functions as ultra-budget weight loss specialist ($199-249/month bundled, $2,388-2,988/year) with ~3 years track record providing semaglutide-only medication with minimal physician consultations through highly streamlined operations serving exclusively obesity treatment without broader men's health services or gender-specialized expertise. This comparison examines complete multi-category men's health consolidation vs ultra-budget medication-only weight loss focus.
Platform Overview
Platform Scope and Service Breadth
Pricing and Cost Structure
Medication Formulary and Treatment Options
Operational Maturity and Platform Reliability
Gender Specialization and Clinical Expertise
Value Proposition and Platform Utility
How We Tested Hims vs Medvi
Our Comparison Methodology
This comparison is based on complete analysis of platform scope, pricing models, gender specialization, multi-category utility, and operational maturity from both platforms, supplemented by peer-reviewed research on weight loss treatment and men's health optimization.
Clinical Evidence: Weight loss treatment recommendations reference FDA-approved GLP-1 medication information (FDA Wegovy Label), semaglutide efficacy from The New England Journal of Medicine, tirzepatide outcomes from NEJM, obesity treatment guidelines from American Association of Clinical Endocrinology, and men's health metabolic factors from Journal of Clinical Endocrinology & Metabolism.
Research Foundation: We analyzed peer-reviewed studies including testosterone and obesity relationships from Obesity Reviews, integrated men's health care from Journal of Men's Health, multi-category telehealth effectiveness from JAMA Network Open, healthcare consolidation benefits from Health Affairs, and compounded medication quality from FDA 503B Guidelines.
Pricing Analysis: All pricing reflects published rates as of January 2026, verified through official platform websites.
Service Verification: Platform capabilities, medication formularies, gender specialization, multi-category services, operational history, and provider credentials were evaluated through detailed review of service scope and specializations.
We maintain independence from both platforms and receive no compensation. Our goal is to provide evidence-based comparison to help you make informed weight loss treatment decisions.
Final Verdict: Hims vs Medvi
Choose hims if: You need complete men's health platform addressing weight loss plus other conditions (erectile dysfunction, hair loss, mental health, skincare), want men's health specialized medical team with expertise in testosterone, sexual function, male metabolic factors vs gender-neutral obesity treatment, seek healthcare consolidation under single provider relationship managing multiple men's health dimensions, value longest-established telehealth operational maturity (7+ years, millions served) providing maximum treatment continuity confidence, need both semaglutide AND tirzepatide medication flexibility, or recognize men managing multiple conditions (weight + ED, weight + hair loss) benefit from integrated multi-category platform vs separate budget specialist subscriptions.
Choose Medvi if: You exclusively need ultra-budget weight loss without other men's health services, prioritize absolute lowest GLP-1 pricing ($2,388-2,988/year) accepting medication-only limitation, satisfied with semaglutide-only formulary without tirzepatide access, accept ~3 years operational history vs hims 7+ years extensive track record, don't require erectile dysfunction treatment, hair loss medications, mental health support, or other men's health services, seek bare-bones medication access without lifestyle programming or complete support, or extreme cost sensitivity drives decision-making over operational reliability, men's health specialization, or multi-category utility.
Bottom line: hims and Medvi represent dramatically different healthcare models—complete multi-category men's health platform vs ultra-budget medication-only weight loss specialist. hims operates as established men's health consolidation ($49-139/month consultations plus medication costs, total $2,000-4,500+/year estimated) with 7+ years operational history serving millions providing weight management integrated with erectile dysfunction, hair loss, mental health, skincare, and primary care through men's health specialized medical team. Medvi functions as ultra-budget weight loss specialist ($199-249/month bundled, $2,388-2,988/year) with ~3 years track record providing semaglutide-only medication with minimal physician consultations through highly streamlined operations serving exclusively obesity treatment. Medvi delivers lowest-cost GLP-1 access but dramatic service limitations: medication-only model, semaglutide-only formulary, gender-neutral treatment, zero multi-category utility. hims higher costs but complete services: men's health specialized expertise, multi-category consolidation (weight + ED + hair loss under single platform), operational maturity (7+ years vs ~3 years), treatment flexibility (semaglutide AND tirzepatide options). For men exclusively needing budget semaglutide accepting medication-only limitation and single-purpose platform, Medvi delivers lowest cost. For men managing multiple men's health conditions or valuing men-specific expertise, operational maturity, and healthcare consolidation, hims complete approach justifies higher costs through multi-utility, specialized care, and extensive track record. Platform choice depends on budget constraints, single vs multi-condition needs, value of men's health specialization, importance of operational maturity, and whether healthcare consolidation across multiple men's health dimensions justifies hims premium over Medvi ultra-budget medication-only model.
Sources & References
Our comparisons are informed by official sources and regulatory guidelines. We encourage readers to verify information with authoritative sources.
- FDA - Semaglutide Safety InformationFDA safety information and warnings for semaglutide medications
- GoodRx - Wegovy (Semaglutide) Drug InformationGoodRx drug guide for Wegovy semaglutide: uses, dosage, side effects, and cost
- FDA - Drug Compounding Laws and PoliciesFederal laws and FDA policies governing drug compounding
- American Telemedicine Association - Why TelemedicineATA overview of telemedicine benefits and effectiveness data
- FSMB - Telemedicine Policy and RegulationFederation of State Medical Boards telemedicine policies and licensing
- CDC - Obesity Data and StatisticsOfficial CDC data and clinical treatment guidelines
- NIDDK - Weight ManagementNIDDK evidence-based guidance on weight management: BMI thresholds, GLP-1 medications, and health risks of obesity.
- KFF - GLP-1 Coverage in Medicare and MedicaidGLP-1 obesity drug coverage policy for Medicare and state Medicaid programs
Editorial Note: Researched and edited by our editorial team. AI tools assist with initial research and drafting; all content is fact-checked and edited by humans before publication. Learn more about our editorial standards
